tbuckley/cabot-search huggingface dataset:
AB0887 Autologous Stem-Cell Transplantation (ASCT) as Treatment Option in A Child with Severe Systemic Sclerosis
Authors: D.S. Lazarevic, J. Vojinovic
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Clinical presentation of systemic sclerosis in overlap syndrome with severe skin involvement can be very severe while standard treatment could be ineffective with necessity to apply autologous stem-cell transplantation (ASCT). <h3>Objectives</h3> After moderate respiratory infection, 6 years old boy PM has developed anorexia, dry mouth and eyes syndrome followed with long-lasting intermittent temperature and heavy weight loss. Few months later he developed bilateral lymph node and parotid gland enlargement followed by both feet and hands swelling and liver and spleen enlargement. ESR was 24, ANA positive, LKM1 antibodies positive, LAC positive with trombophillia type coagulation defect. Echocardiography has shown thrombus in right atrium and he was found to be heterozygote for MTHFR gene mutation. Final diagnosis was not established and steroids 0,3mg/kg/day were commenced. One year later skin on feet and hands became purple and erytematous, extremely dry with squamouse plaques with flexion contractures of the fingers. Proximal muscle weakness with Achilles tendons shortening was present. Skin on the face and trunk was tight, erythematous, sqamous with reddish eyelids; extreme kserostomia and kserophtalmia were present with limited possibility to open mouth and extreme parotid gland enlargement. Muscle and skin biopsy has shown sclerodermatous changes in skin, vasculitis and panniculitis in subcutaneous layer and DM type of inflammatory myophaty. EMNG test was extremely myophatic. Lung CT has revealed first signs of lung fibrosis. During the last seven years he had severe episodes of ulcerous skin vasculitis and was treated with multiple methyl-prednisolone boluses and oral steroids in combination with different DMARDs (methotrexate, CysA, azathioprine, cyclophosphamide pulses), as well as several rituximab cycles, but with limited response. During the time skin involvement was progressive with almost all skin affected, with sclerodactilia, joint contractures and extreme disability. ASCT, as the last treatment option, was performed two years ago. After ASCT our patient is clinically stabile, without further progression of skin changes, reduced steroid treatment (5mg/day) and only persistent side effect present is hypogamaglobulinemia with necessity for iv immunoglobulin substitution. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4710
Abstract 4085: Inhibition of rodent mammary carcinogenesis by wheel running and/or dietary energy restriction
Authors: Weiqin Jiang, Zongjian Zhu, John N. McGinley, Jarrod Zacher, Elizabeth Neil, Henry J. Thompson
Journal: Cancer Research (2011)

Abstract The prevention of breast cancer by the combined effects of physical activity (PA) and dietary energy restriction (DER) has received limited investigation. The objective of this experiment was to determine the inhibitory effects of PA and/or DER on mammary carcinogenesis and associated mechanisms. Female Sprague Dawley rats were injected with 1-methyl-1-nitrosourea (50 mg/kg) and 7 days thereafter randomized to: 1) sedentary control, 2) PA at 3000 revolutions (3.36 km) per day; or the energy balance equivalents of PA: 3) 20% DER or 4) PA at 1500 revolutions per day + 10% DER. In order to investigate the effects of physical activity at a constant intensity, rats were given free access to a motorized activity wheel (55 m/min) with reinforcement of running behavior using a food reward system. The duration of this experiment was 8 weeks. As intended, final body weights of the sedentary control were higher than PA, DER or PA&amp;DER, but the intervention groups had similar final weights. Overall, PA and/or DER reduced mammary cancer incidence, cancer multiplicity, and tumor burden and prolonged cancer latency (p&amp;lt;0.05) in comparison to the sedentary control group. However, the differences in these cancer endpoints among the intervention groups were not statistically different. Experiments are in progress to determine the extent to which host systemic factors and cell autonomous mechanisms are differentially affect by PA, DER, or their combination in this context of energy balance equivalence. Supported by PHS grant CA100693 from the National Cancer Institute. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4085. doi:10.1158/1538-7445.AM2011-4085
Papillary Thyroid Carcinoma Associated with Parathyroid Adenoma Detected by Pertechnetate–MIBI Subtraction Scintigraphy
Authors: D Rubello, A Toniato, M R Pelizzo, D Casara
Journal: Clinical Nuclear Medicine (2000)

Two cases of papillary thyroid carcinoma coexisting with a parathyroid adenoma are reported. A double-tracer pertechnetate–MIBI subtraction scan combined with neck ultrasound correctly visualized the site of the parathyroid adenoma despite the presence of thyroid nodule(s) located in the opposite thyroid lobe in one case and in both thyroid lobes in the other case. In both patients, the papillary thyroid carcinoma was cold with Tc-99m pertechnetate and hot with MIBI. Total thyroidectomy and parathyroidectomy of a solitary parathyroid adenoma were performed in both patients. Pertechnetate–MIBI subtraction scanning associated with neck ultrasound appears to be a useful imaging technique to detect parathyroid adenoma before operation in patients with concomitant thyroid nodular disease. A MIBI-hot and Tc-99m pertechnetate–cold thyroid nodule can indicate the possible presence of a malignant lesion.
Transnasal flexible bronchoscopic implantation of a nickel titanium (NiTi) bronchial occlusive device for a bronchobiliary fistula
Authors: Y. Shang, C. Bai, X. Yao, Y. Huang, L. Zhao, Q. Li
Journal: Endoscopy (2010)

Bronchobiliary fistula (BBF) is rarely seen, and its management can be challenging [1] [2]. Although conventional surgical repair is effective, it is a complicated and traumatic procedure [3] [4]. To overcome this difficulty, we have developed a set of nickel titanium (NiTi) bronchial occlusive implantation devices and we have successfully implanted one device in a patient with a BBF.
Thymus Accumulation of I-131 After Therapeutic Dose for Thyroid Carcinoma
Authors: J. P. MURATET, P. GIRAUD
Journal: Clinical Nuclear Medicine (1996)

Eight months after initial I-131 ablative therapy for papillary carcinoma in a 22-year-old woman, a second I-131 treatment was performed and a post-therapeutic study demonstrated increased activity in the upper mediastinum. Mediastinal uptake was not thought to represent a metastasis because of the low thyroglobulin level. Thymic origin was suspected on dual isotope SPECT I-131 studies and Tc-99m MDP and confirmed on a CT scan. Visualization of the thymus is not common during I-131 post-therapeutic imaging and dual-isotope SPECT is a useful tool to identify uptake at this site.
P17.59 * TRANSPLANTED MGMTP140K GENE-MODIFIED CD34+ CELLS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA CHEMO-PROTECT BONE MARROW AND LEAD TO PROLONGED SURVIVAL
Authors: M. M. Mrugala, J. E. Adair, B. C. Beard, D. L. Silbergeld, L. Halasz, J. K. Rockhill, H. Kiem
Journal: Neuro-Oncology (2014)

BACKGROUND: Glioblastoma is the most aggressive adult primary malignant brain tumor. It is associated with poor prognosis (median survival of 12-15 months) despite treatment. Combination chemotherapy with carmustine (BCNU) or temozolomide (TMZ) with the MGMT inhibitor O6-benzylguanine (O6BG) has been used but it has been associated with dose limiting hematopoietic toxicity. OBJECTIVE: To assess safety and efficacy of a retroviral vector encoding the O6BG-resistant MGMTP140K gene for transduction and autologous transplantation of hematopoietic stem cells (HSCs) in MGMT unmethylated, newly diagnosed GBM patients in an attempt to chemoprotect bone marrow during combination O6BG/TMZ therapy. METHODS: Seven patients have been enrolled in the first cohort of the study. Following tumor resection, patients underwent standard radiation therapy without TMZ followed by G-CSF mobilization, aphaeresis and conditioning with 600 mg/m2 BCNU prior to infusion of gene-modified cells. Post transplant, patients were treated with 28-day cycles of single dose TMZ (472mg/m2) with 48-hour intravenous O6BG (120mg/m2 bolus, followed by 30mg/m2/24h). RESULTS: The BCNU dose was nonmyeloablative. Gene marking in pre-infusion colony forming units (CFUs) was robust in most patients. Similarly, following engraftment, gene marking in white blood cells and sorted granulocytes assessed by real-time PCR was high. Patients have received up to nine cycles of O6BG/TMZ with evidence for selection of gene-modified cells and tolerable hematologic toxicity. This is significantly more cycles compared to recurrent patients receiving O6BG/TMZ in the absence of gene modified, chemoprotected cells (Quinn et al., 2005) (p < 0.05). No extra-hematopoietic toxicity has been observed thus far and all seven patients exhibited improved survival over historical controls. The longest surviving patient is 56+ months from the diagnosis without evidence of disease progression. CONCLUSIONS: These data demonstrate feasibility of achieving significant engraftment of MGMTP140K- modified cells with a well-tolerated dose of BCNU. Combination of TMZ and O6BG is well tolerated in this setting and patients with newly diagnosed GBM exhibiting unmethylated MGMT promoter achieve prolonged survivals.
Abstract 4187: Regulation of NRSF/REST by miR-217; Implications during pancreatic acinar ductal trans-differentiation.
Authors: Ana Clara P. Azevedo-Pouly, Jinmai Jiang, Dhruvitkumar Sutaria, Thomas Schmittgen
Journal: Cancer Research (2013)

Abstract Pancreatic ductal adenocarcinoma is believed to arise from exocrine acinar cells following trans-differentiation to cells with a more epithelial phenotype. A pancreas enriched cluster of miRNAs (miR-216a/b-217) is located on chromosomes 2 and 11 in humans and mice, respectively. These miRNAs are significantly reduced in patient's tumor specimens and during tumor progression in a transgenic mouse model of pancreatic ductal adenocarcinoma. To investigate a role for miR-216/-217 during acinar ductal trans-differentiation, we used a model by which primary mouse pancreatic acini trans-differentiate into epithelial-like cells when cultured on matrigel. Over a 4 day culture period, the acini develop an epithelial morphology and display reduced mRNA expression of the acinar marker amylase, increased expression of the epithelial marker cytokeratin-19 (KRT19) and reduced expression miR-216/-217. Forced expression of miR-217 using a lentiviral vector (LV) decreased KRT19 mRNA expression compared to the empty vector control treated cells on day 4 of the trans-differentiation. To implicate miR-217 targets in regulating acinar trans-differentiation, we considered REST/NRSF, a transcriptional repressor of neuronal genes in non-neuronal tissues. REST mRNA expression increased during the 4 day trans-differentiation implying regulation of REST by miR-217. Regulation of REST by miR-217 was validated using a luciferase assay and western blotting. Furthermore, two REST target genes were upregulated by the miR-217 LV on day 4 of the trans-differentiation. Studies are ongoing to determine if this increase in expression results from miR-217 suppressing REST protein levels. Additionally, miR-217 LV infection of 3 pancreas cancer cell lines reduced REST protein and caused significant cell death. Our current focus is to establish a link between miR-217 suppression of REST and cell death. We report a connection between reduced miR-217 in several pancreas model systems. We hypothesize a novel role for REST in pancreas homeostasis and cancer. Citation Format: Ana Clara P. Azevedo-Pouly, Jinmai Jiang, Dhruvitkumar Sutaria, Thomas Schmittgen. Regulation of NRSF/REST by miR-217; Implications during pancreatic acinar ductal trans-differentiation. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4187. doi:10.1158/1538-7445.AM2013-4187
Effect of Thiazides on Carbohydrate Metabolism in Patients with Hypertension
Authors: Alvin P. Shapiro, Thomas G. Benedek, Jean L. Small
Journal: New England Journal of Medicine (1961)

THE present report concerns a systematic investigation of the diabetogenic effect of the thiazide drugs. Its purpose was threefold: to obtain additional data concerning the clinical nature and severity of this effect, for although a number of case reports have appeared, few planned studies are available1 2 3 4 5 6; to study the incidence and development of "thiazide diabetes" in a hypertensive population in whom the drugs are used widely and among whom the concomitant existence of diabetes mellitus is not uncommon7; and to investigate possible mechanisms of this iatrogenic change in carbohydrate metabolism. The recognition of 5 patients with this disturbance . . .
Nicotine Patch Use in the General Population: Results From the 1993 California Tobacco Survey
Authors: J. P. Pierce, E. Gilpin, A. J. Farkas
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Nicotine Patch Use in the General Population: Results From the 1993 California Tobacco Survey Get access John P. Pierce, John P. Pierce Cancer Prevention and Control Program, Cancer Center, University of CaliforniaSan Diego, La Jolla 1 Correspondence to. John P. Pierce, Ph.D., Cancer Prevention and Control Program, University of California Cancer Center, La Jolla, CA 92093-0901. Search for other works by this author on: Oxford Academic PubMed Google Scholar Elizabeth Gilpin, Elizabeth Gilpin Cancer Prevention and Control Program, Cancer Center, University of CaliforniaSan Diego, La Jolla Search for other works by this author on: Oxford Academic PubMed Google Scholar Arthur J. Farkas Arthur J. Farkas Cancer Prevention and Control Program, Cancer Center, University of CaliforniaSan Diego, La Jolla Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 2, 18 January 1995, Pages 87–93, https://doi.org/10.1093/jnci/87.2.87 Published: 18 January 1995 Article history Received: 07 June 1994 Revision received: 21 September 1994 Accepted: 06 October 1994 Published: 18 January 1995
Group D Streptococcal Bacteremia, with Emphasis on the Incidence and Presentation of Infections Due to<i>Streptococcus bovis</i>
Authors: William D. Ravreby, Edward J. Bottone, Gerald T. Keusch
Journal: New England Journal of Medicine (1973)

Procedures routinely in use in many hospital microbiology laboratories do not distinguish between enterococci and nonenterococcal Group D streptococci. During a 15-month period we observed 11 patients with bacterial endocarditis due to Group D streptococci, eight of which were due to the nonenterococcal species, Streptococcus bovis. This micro-organism showed in vitro susceptibility to a wide variety of antimicrobial agents, including oxacillin and lincomycin. In patients with S. bovis infection, high serum bacteriostatic and bactericidal levels were achieved with penicillin or clindamycin alone, or penicillin and an aminoglycoside. The clinical response was equivalent with all drug regimens. In contrast, enterococci were more resistant in vitro to antibiotics, and in vivo definitely lower serum bactericidal activity was achieved. Infections due to S. bovis are probably often misdiagnosed. It is of clinical importance to distinguish S. bovis from the enterococci because therapy for the former species may not require potentially toxic antimicrobial combinations for a satisfactory therapeutic response. (N Engl J Med 289:1400–1403, 1973)
P1198 EFFECTIVENESS OF TRIPLE THERAPY IN CLINICAL PRACTICE FOR TREATMENT-NAIVE HCV PATIENTS WITH ADVANCED HEPATIC FIBROSIS. VIROLOGIC RESPONSE DATA AT 12 WEEKS POST-TREATMENT (SVR-12W)
Authors: M. Prieto, J. Pascasio, C. Vinaixa, A. Gila, M. Serra, E. Ruiz Escolano, M. Cuaresma, J. Urquijo, R. Millán, J. Sánchez Ruano, S. Alonso, D. Espinosa, J. Navarro-Jarabo, M. Testillano, J. Pons, F. Jorquera, M. Fernandez Bermejo, J. Fuentes, H. Hallal, M. Estévez Escobar, E. Molina Pérez, C. Llamoza, R. Berenguer, J. Salmerón
Journal: Journal of Hepatology (2014)
PHARMACODYNAMIC EFFECTS OF SKIPPING TICAGRELOR MAINTENANCE DOSING FOLLOWING LOADING DOSE ADMINISTRATION
Authors: Fabiana Rollini, Francesco Franchi, Jung Rae Cho, Mona Bhatti, Christopher DeGroat, Kamaldeep Singh, Zeina Alobaidi, Elisabetta Ferrante, Ana Muniz-Lozano, Ryan E. Wilson, Latonya Been, Martin Zenni, Luis Guzman, Theodore Bass, Dominick Angiolillo
Journal: Journal of the American College of Cardiology (2015)
DIFFERENTIAL TREATMENT EFFECTS OF EXTENDED-RELEASE NIACIN AND PLACEBO ON BASELINE AND ONE-YEAR LIPOPROTEIN SUBFRACTIONS AND THEIR RELATIONSHIP TO CARDIOVASCULAR OUTCOMES: POST HOC SUBSET ANALYSIS OF AIM-HIGH TRIAL PATIENTS WITH HIGH TRIGLYCERIDE AND LOW HDL-C
Authors: Peter P. Toth, Steven Jones, April Slee, Santica Marcovina, Jerome Fleg, William Boden
Journal: Journal of the American College of Cardiology (2016)
PTH-249 Contraceptive pill and b12: low yield from investigating low serum b12 in women taking the ocp
Authors: K Clark, L Chinnappan, I Reilly, C Probert
Journal: Gut (2015)

<h3>Introduction</h3> Vitamin B12 deficiency causes megaloblastic anaemia, cytopenias and neurological deficits and deficiency is usually a result of defective absorption, either through lack of intrinsic factor, gastric pathology or ileal pathology although dietary deficiency may occur. Serum B12 assays have low specificity and up to 50% of results below 200 ng/l appear erroneous. Patients could be committed to unnecessary B12 replacement therapy and symptoms may be wrongly ascribed to B12 deficiency as the real cause is overlooked. 70–90% of serum B12 is bound to holohaptocorrin, the remainder being bound to holotranscobalamin. These carrier proteins are affected by pregnancy and the oral contraceptive pill (OCP), resulting in a low B12 level in the absence of anaemia or macrocytosis. Our aim was to evaluate B12 testing in women of childbearing age by assessing firstly, concomitant use of the OCP and secondly where, the result was felt to indicate true deficiency, whether appropriate assessment was conducted. <h3>Method</h3> Over a 12-month period, all women of childbearing age who were shown to have a low serum B12 level were eligible to be included. Repeat tests were excluded. We then reviewed Hb, MCV and ferritin and folate. Results of investigation were noted when performed including intrinsic factor, anti-GPC and TTG antibodies; endoscopy and small bowel imaging. <h3>Results</h3> 180 case records were identified, complete data was available from 166. The two key groups are those with isolated low B12 and those with macrocytic anaemia. Of those with macrocytic anaemia, 4/10 had coexisting folate deficiency. Further assessment was inconsistent- 4/10 no further assessment, 2/10 further blood tests but no imaging and 4/10 had various tests. One patient was subsequently diagnosed with Crohn’s disease. Those patients with an isolated low B12 result, 68 were taking the OCP. For the remainder there was no documentation to confirm or deny use. Of the 68 patients, 30/68 had undergone some form of further investigation. In 2/30 women taking the OCP with low B12 without anaemia, one had coeliac disease and one had anti-GC antibodies (but no IF antibodies). <h3>Conclusion</h3> In those patients who are identified as having a low B12 level in the absence of anaemia or macrocytosis; use of the OCP should be considered. Investigation of low B12, when there is no anaemia and normocytosis, is unrewarding. Repeating the serum B12 level after stopping the OCP should confirm the cause and prevent unnecessary investigation. Where anaemia or macrocytosis is present a structured approach to further investigation should made to seek and identify significant pathology. This includes antibody testing, thyroid function and gastric + ileal assessment. <h3>Disclosure of interest</h3> None Declared.
Abstract 3353: The CD44 hi cell population from malignant pleural effusion derived lung tumors displays increased tumorigenic potential
Authors: Saroj Basak, Mysore Veena, Scott Oh, Eri Srivatsan, Raj K. Batra
Journal: Cancer Research (2010)

Abstract We have developed a new model system (http://dx.plos.org/10.1371/journal.pone.0005884) to test whether we can isolate candidate Cancer Stem Cell (CSC) populations from clinical specimens and validate that they possess increased tumorigenic and/or metastogenic potential. The model utilizes primary tumor cell populations derived from human malignant pleural effusions (MPE), which are cultured in an autologous tumor microenvironment (TME). This model system maintains intratumoral heterogeneity, and contains molecular signatures, surface phenotypes, and metabolic biomarkers that are associated with candidate CSC. The current study compares isogenic primary tumor subpopulations, separated on the basis of a surface biomarker expression, in terms of differences in molecular marker expression, and bioassays that measure clonogenic efficiency and tumorigenic potential. CD44, a surface CSC-biomarker, is expressed on most of the primary tumor cells (75-95%) derived from MPE. The CD44 expressing tumor cells can be divided into two groups (CD44hi) and (CD44lo) on the basis of CD44 surface labeling intensity. The CD44hi and CD44lo tumor cells were sorted (10% of each) from total tumor cell populations by FACS and evaluated for their clonogenicity on plastic (colony forming efficiency) and for colony forming units in soft agar (anchorage independent growth). Studies show that the CD44hi tumor cells are 40-60% more efficient in forming colonies, and give rise to larger colonies than CD44lo tumor cells. Expression of other candidate CSC biomarkers was also compared in the two cell subsets to determine the molecular correlates of CD44hi versus CD44lo cells. CD44hi cells coexpress higher levels of BMI-1, hTERT, EZH2, and OCT-4 by RT-PCR than CD44lo tumor cells, but there is no apparent difference in the expression of SUZ12 between these two populations. CD44hi cells also have increased ALDH expression based on the Aldefluor assay. To determine whether these subpopulations differed in terms of tumorigenic potential, limiting dilutions of cells were heterotopically (subcutaneous flank region) injected in NOD/SCID (IL-2gRnull) mice in comparison to CD44lo tumor cells. Low numbers of CD44hi cells (down to 300 cells) efficiently formed tumors, whereas isogenic CD44lo tumor cells failed to form tumors at the same cell doses. Thus, CD44hi cells have higher tumorigenic potential than CD44lo cells, and these studies suggest that these primary tumor populations are preferentially enriched for the candidate CSC phenotype. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3353.